Lonza nominates Juan Andres and Eric Drapé as independent Board Members

Today, the Lonza Board of Directors announced the nomination of Juan Andres and Eric Drapé as Independent Members of the Board. The Board will propose to shareholders the election of both nominees at the Lonza Group Annual General Meeting (AGM) in May 2025.

This announcement follows a recent update which reported measures to improve Board governance, succession planning and focus on organizational health. Building on these changes, the two new proposed members will increase the Board’s size to ten.

Juan Andres, a Spanish national, has a career spanning more than 35 years during which he has held a variety of leadership positions. Most recently he was President, Strategic Partnerships and Enterprise Expansion at Moderna, where he led the technical development, scale-up and worldwide supply of its COVID-19 mRNA vaccine. Before joining Moderna, Juan held roles as Head of Technical Operations as well as Head of Quality at Novartis. Prior to that, he spent more than 15 years at Eli Lilly. Juan’s deep understanding of the pharma and biotech industry is complemented by international business expertise, having spent time in Puerto Rico, Spain, Switzerland, the UK and the US. Juan is a Board Member at Avantor.

Eric Drapé, a French national, most recently held the role of EVP, Head of Global Operations, Company Officer and Member of the Executive Committee at Teva Pharmaceuticals. In this role, he oversaw operations across more than 50 sites. For more than 35 years, Eric has served in multiple leadership roles in the pharmaceutical industry, covering global operations and quality at Teva Pharmaceuticals, Ipsen Pharma and Novo Nordisk. He brings a wealth of international experience, having held positions in the Denmark, France, Israel and the US. Eric Drapé will join the Board after the expiry of current contractual commitments, effective 14 May 2025.

I would like to take this chance to congratulate Juan and Eric on behalf of the Board for their nomination. Both nominees share extensive leadership experience, alongside diverse and complementary backgrounds that are well suited to Lonza today. Juan brings strong strategic capabilities, and both leaders bring deep manufacturing expertise that is highly relevant for our business. Juan and Eric know the CDMO industry well and have been customers of Lonza in the past. This fresh external perspective will bring valuable insights to support our focus on delivering innovation, operational excellence, and outstanding customer service.”

Jean-Marc Huët, Board Chairman, Lonza

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Lonza. (2024, September 20). Lonza nominates Juan Andres and Eric Drapé as independent Board Members. News-Medical. Retrieved on October 11, 2024 from https://www.news-medical.net/news/20240920/Lonza-nominates-Juan-Andres-and-Eric-Drape-as-independent-Board-Members.aspx.

  • MLA

    Lonza. "Lonza nominates Juan Andres and Eric Drapé as independent Board Members". News-Medical. 11 October 2024. <https://www.news-medical.net/news/20240920/Lonza-nominates-Juan-Andres-and-Eric-Drape-as-independent-Board-Members.aspx>.

  • Chicago

    Lonza. "Lonza nominates Juan Andres and Eric Drapé as independent Board Members". News-Medical. https://www.news-medical.net/news/20240920/Lonza-nominates-Juan-Andres-and-Eric-Drape-as-independent-Board-Members.aspx. (accessed October 11, 2024).

  • Harvard

    Lonza. 2024. Lonza nominates Juan Andres and Eric Drapé as independent Board Members. News-Medical, viewed 11 October 2024, https://www.news-medical.net/news/20240920/Lonza-nominates-Juan-Andres-and-Eric-Drape-as-independent-Board-Members.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Lonza and Nephron to present results of MODA-ES Platform implementation at 2019 ISPE Meeting & Expo